Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Exercise Capacity Study Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (PAH)

Trial Profile

A Phase III, Exercise Capacity Study Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (PAH)

Planning
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs Ralinepag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms ADVANCE ENDURANCE 304
  • Most Recent Events

    • 14 Aug 2018 New trial record
    • 06 Aug 2018 According to an Arena Pharmaceuticals media release, the company expect to initiate this trial in Q1:19.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top